Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials
Conclusion: DPL improved endoscopic, clinical, radiologic and pt-reported outcomes similarly in CRSwNP pts with/without NASID-ERD and was well tolerated. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Mullol, J., Laidlaw, T. M., Amin, N., Bachert, C., Han, J. K., Hellings, P. W., Canonica, G. W., Cho, S. H., Maspero, J. F., Desrosiers, M., Hopkins, C., Paggiaro, P., Zhang, M., Lu, X., Patel, N., Graham, N. M. H., Staudinger, H., Mannent, L. P. Tags: Airway pharmacology and treatment Source Type: research
Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma
Conclusion: MF 80 and 320 μg, delivered via Breezhaler®, is non-inferior to MF at 200 and 800 μg, delivered via Twisthaler®. Including ICS sensitivity in the model improves model robustness. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Buhl, R., Tanase, A.-M., Hosoe, M., Cao, W., Demin, I., Bartels, C., Jauernig, J., Ziegler, D., Patalano, F., Hederer, B., Kanniess, F., Tillmann, H.-C. Tags: Airway pharmacology and treatment Source Type: research
Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis
GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 13, 2019 Category: Allergy & Immunology Authors: Charles P. Andrews, Dale Mohar, Yacine Salhi, Sudeesh K. Tantry Source Type: research
Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings
Global initiative for asthma (GINA) 2019 recommends adding a long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS) as a maintenance controller therapy in patients with inadequately controlled asthma. Indacaterol acetate (IND, a LABA) in combination with mometasone furoate (MF, an ICS) is under development for the treatment of these patients. (Source: Respiratory Medicine)
Source: Respiratory Medicine - November 13, 2019 Category: Respiratory Medicine Authors: Oliver Kornmann, Janos Mucsi, Nadezda Kolosa, Lorraine Bandelli, Biswajit Sen, Lisa C. Satlin, Peter D'Andrea Source Type: research
Efficacy and Safety of Twice-daily and Once-daily Olopatadine-Mometasone Combination Nasal Spray for Seasonal Allergic Rhinitis.
CONCLUSION: Twice-daily GSP301 treatment was efficacious and well tolerated, providing statistically significant and clinically meaningful improvements in rTNSS (primary endpoint) versus placebo and both monotherapies.
PMID: 31734334 [PubMed - as supplied by publisher] (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 13, 2019 Category: Allergy & Immunology Authors: Andrews CP, Mohar D, Salhi Y, Tantry SK Tags: Ann Allergy Asthma Immunol Source Type: research
